The Report Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis By Drug Type (Antacids, Proton Pump Inhibitors,
H2 Receptor Blocker, Pro-Kinetic Agents), By Region, And Segment Forecasts,
2018 – 2025
The global Gastroesophageal Reflux Disease (GERD) therapeutics market is expected to reach USD 4.34 billion by 2025,
according to a new study by Grand View Research, Inc. The incidence of acid
reflux disorder, also known as heartburn, is rapidly increasing worldwide.
Various studies state that almost every person experiences acid reflux once in
a lifetime.
The overall market has
been experiencing a downturn in terms of revenue in the past several years as
the leading drugs for GERD treatment have lost their patent protection, with
their market shares now largely consumed by over-the-counter (OTC) and generic
medications. Although loss of exclusivity of high-grossing drugs have caused a
market fall-off, the demand for acid reducing drugs due to the high prevalence
and incidence levels of GERD will prove beneficial to the industry from a
commercial standpoint.
GERD is one of the
commonly observed recurrent gastrointestinal disorders worldwide. The
prevalence of acid reflux and related symptoms has increased across the globe
by nearly 50% over the last decade. This disorder not only has major effects on
the health and quality of patient lives, but also extends to the healthcare
system and economy.
In addition, the
occurrence of acid reflux disease increases with age, rendering elderly people
more prone to developing a severe form of heartburn. The geriatric subset hence
forms a prominent target population for GERD therapeutics.
Access Research Report of Gastroesophageal
Reflux Disease Therapeutics Market @ www.grandviewresearch.com/industry-analysis/gastroesophageal-reflux-disease-gerd-therapeutics-market
Further key findings from the study suggest:
· Antacids have been identified as the
largest drug type segment in terms of revenue share due to their
cost-effectiveness and greater consumer accessibility
· The rising trend of self-medication in case
of heartburn is particularly responsible for the growth in sales of OTC
antacids
· Proton pump inhibitors accounted for the
second largest segment as they are the most commonly prescribed medication for
the treatment of acid reflux
· Market share of proton pump inhibitors is expected
to decline over the forecast period with the loss of patent protection of
several leading drugs, such as Nexium and Prilosec, in this segment
· North America accounted for the largest
regional market in 2016 owing to the presence of a large patient population
suffering from heartburn and the availability of OTC generics
· On the other hand, Asia Pacific is expected
to grow at a fairly high growth rate as compared to other regional markets due
to increased adoption of OTC and generic antacids along with rising prevalence
of heartburn
Grand View Research has
segmented the GERD therapeutics market on the basis of drug type and region:
GERD Therapeutics Drug Type Outlook (Revenue, USD
Million, 2014 - 2025)
·
Antacids
·
H2 Receptor Blockers
·
Proton Pump Inhibitors (PPIs)
·
Pro-kinetic agents
GERD Therapeutics Regional Outlook (Revenue, USD Million,
2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa (MEA)
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, we offer market intelligence
studies ensuring relevant and fact-based research across a range of industries,
from technology to chemicals, materials and healthcare.
No comments:
Post a Comment